452 related articles for article (PubMed ID: 29025857)
21. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
Iwama S; Arima H
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):90-94. PubMed ID: 28603206
[TBL] [Abstract][Full Text] [Related]
22. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
23. Endocrine toxicities of immune checkpoint inhibitors.
Wright JJ; Powers AC; Johnson DB
Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
[TBL] [Abstract][Full Text] [Related]
24. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
[TBL] [Abstract][Full Text] [Related]
25. [Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors].
Inaba H; Ariyasu H; Kurimoto C; Iwakura H; Akamizu T
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1031-1035. PubMed ID: 30042266
[TBL] [Abstract][Full Text] [Related]
26. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
27. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.
Zhao C; Tella SH; Del Rivero J; Kommalapati A; Ebenuwa I; Gulley J; Strauss J; Brownell I
J Clin Endocrinol Metab; 2018 Feb; 103(2):365-369. PubMed ID: 29220526
[TBL] [Abstract][Full Text] [Related]
29. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
30. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
[TBL] [Abstract][Full Text] [Related]
31. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor-associated hypercalcaemia.
Izzedine H; Chazal T; Wanchoo R; Jhaveri KD
Nephrol Dial Transplant; 2022 Aug; 37(9):1598-1608. PubMed ID: 33374000
[TBL] [Abstract][Full Text] [Related]
33. Endocrine dysfunction following immune checkpoint inhibitor therapy.
Konda B; Nabhan F; Shah MH
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
[TBL] [Abstract][Full Text] [Related]
34. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.
Girotra M; Hansen A; Farooki A; Byun DJ; Min L; Creelan BC; Callahan MK; Atkins MB; Sharon E; Antonia SJ; West P; Gravell AE;
JNCI Cancer Spectr; 2018 Jul; 2(3):pky021. PubMed ID: 30057972
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
Faje A
Pituitary; 2016 Feb; 19(1):82-92. PubMed ID: 26186958
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
38. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
Atkinson M; Lansdown AJ
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 EXPRESSION IN NORMAL ENDOCRINE TISSUES IS NOT INCREASED DESPITE HIGH INCIDENCE OF PD-1 INHIBITOR-ASSOCIATED ENDOCRINOPATHIES.
Pollack R; Kagan M; Dresner-Pollak R; Neuman T
Endocr Pract; 2021 Jan; 27(1):34-37. PubMed ID: 33475499
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-related hypophysitis.
Mizukoshi T; Fukuoka H; Takahashi Y
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
